N-Acetyl Selank
An acetylated derivative of the anxiolytic heptapeptide Selank, engineered for greater enzymatic stability and CNS bioavailability.
N-Acetyl Selank is an acetylated analog of Selank (TKPRPGP), a synthetic tuftsin-derived heptapeptide developed as an anxiolytic and nootropic. N-acetylation at the N-terminus is proposed to improve resistance to enzymatic degradation and potentially alter blood-brain barrier permeability, with the expectation of enhanced CNS bioavailability and duration of action relative to the parent compound. It is most often used intranasally as a research chemical. No studies indexed in PubMed examine N-acetyl Selank as a distinct compound, so its pharmacology is inferred almost entirely from the parent peptide.
Class
Acetylated synthetic heptapeptide (tuftsin-derived Selank derivative)
Routes
Intranasal, Subcutaneous
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Anxiolytic effect
The parent peptide Selank produces anxiolytic effects in preclinical models and limited Russian human studies, attributed to modulation of the GABA-A receptor complex; N-acetyl Selank is presumed to retain this activity with modified pharmacokinetics.
Cognitive enhancement
Documented research areas include cognitive enhancement and nootropic effects, thought to arise from serotonergic and enkephalinergic modulation. Evidence is inferred from Selank rather than the analog itself.
Memory support
Memory is among the primary research areas associated with the Selank family, linked to influence on limbic-system neurotransmission. Direct data on the acetylated form is absent.
Stress reduction
Selank has been studied for stress reduction and mood stability; the acetylated derivative is marketed on the expectation of similar receptor interactions with longer duration of action.
Enhanced bioavailability (proposed)
N-acetylation at the N-terminus is proposed to increase resistance to enzymatic breakdown and improve CNS bioavailability compared with unmodified Selank, the main rationale for the analog.
Mechanism
How it works
N-Acetyl Selank is derived from Selank, a synthetic heptapeptide (TKPRPGP) based on a tuftsin sequence. The parent peptide acts through several central nervous system pathways: it modulates the GABA-A receptor complex to produce anxiolytic effects, increases enkephalin levels in the limbic system, and influences serotonin metabolism, together producing anxiolytic and nootropic actions.
The N-acetyl modification adds an acetyl group at the N-terminus. This structural change is proposed to improve resistance to enzymatic degradation by aminopeptidases and to potentially alter blood-brain barrier permeability, with the intended result of enhanced CNS bioavailability and a longer duration of action than the parent compound.
Importantly, these mechanistic claims for the acetylated analog are extrapolated from Selank. No publications indexed in PubMed specifically examine N-acetyl Selank, and no independent preclinical studies or pharmacokinetic comparisons with the parent peptide exist, so its receptor interactions and pharmacokinetics in humans remain uncharacterized.
Combinations
Stacking & blends
Selank family with N-Acetyl Semax
Combined anxiolytic and cognitive/nootropic support
The acetylated Semax and Selank analogs are frequently paired in nootropic research contexts, with Selank contributing anxiolytic and calming effects and Semax contributing stimulatory cognitive and neuroprotective effects. This pairing is a community convention rather than a clinically validated stack.
Safety
Side effects & considerations
Contraindications & cautions
- Pregnancy or nursing
N-Acetyl Selank is generally considered lower risk in research contexts, but its safety profile as a distinct compound is entirely uncharacterized in the indexed literature. Individual response varies; review all considerations before use.
FAQ
N-Acetyl Selank — common questions
What is N-Acetyl Selank?
It is an acetylated derivative of Selank (TKPRPGP), a synthetic heptapeptide anxiolytic developed from a tuftsin-based sequence. N-acetylation at the N-terminus is proposed to improve resistance to enzymatic degradation and alter blood-brain barrier permeability, with the goal of enhanced CNS bioavailability and duration of action.
What is N-Acetyl Selank studied for?
Primary research areas include anxiolytic effects, cognitive enhancement, memory, stress reduction, and mood stability. These are inferred largely from the parent compound Selank.
How is it administered?
It is most commonly used intranasally as a nasal spray, and subcutaneous injection is also reported. Products appear in vials, capsules, and sprays.
Is there human clinical evidence for N-Acetyl Selank?
No. No publications indexed in PubMed examine N-acetyl Selank as a distinct compound, and there are no human clinical trials, independent preclinical studies, or pharmacokinetic comparisons with the parent Selank. Its properties are extrapolated from Selank.
Is N-Acetyl Selank approved or legal to use?
It has no FDA approval and no approved indication in any jurisdiction. It is available only as a research chemical and is not a medicine or dietary supplement.
What are the contraindications?
Reported contraindications include pregnancy or nursing. Because its safety profile is uncharacterized, a qualified healthcare professional should be consulted before any use.
